EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference

Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets’ Ophthalmology Conference that ...

This Fish Lives Where Sunlight Goes To Die And Sees Just Fine — A Biologist Explains How

This bizarre-looking fish may seem otherworldly, but every part of its design solves a real problem: how to see, hunt and ...
The Lancet

Artificial intelligence for post-treatment prediction in age-related macular degeneration

Ophthalmology pioneered the clinical use of artificial intelligence (AI). Beyond automating routine tasks, including retinal ...

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug ...

Kodiak Sciences Inc.: Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda ...

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving ...
Ophthalmology Advisor

Low-Cylinder-Power Toric IOLs Better Reduce Astigmatism Better Than Nontorics

Low-cylinder-power toric IOLs significantly reduce refractive astigmatism and improve visual acuity in eyes with mild corneal astigmatism.